MMMary C. Moran

Mary C. Moran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mary C. Moran has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Diarrhea-associated Mortality in Children Less Than 5 Years of Age in the United States, 2005–2024

    by Mary C. Moran, Aaron T. Curns, Umesh D. Parashar, Jacqueline E. Tate

    Background: The introduction of rotavirus vaccines in the United States in 2006 and 2008 has had large impacts on reducing rotavirus- and diarrhea-associated healthcare utilization. We evaluated changes in diarrhea-associated mortality from 2005 to 2024 among children 1–59 months of age. Methods: We examined diarrhea-associated deaths, identified by International Classification and Diagnostic codes related to diarrhea listed anywhere on the death certificate, reported to the National Center for Health Statistics from 2005 to 2024. Diarrhea-associated death rates were calculated using national census data. Rate ratios and 95% confidence intervals were calculated using Poisson regression. Results: From 2005 to 2024, 6993 diarrhea-associated deaths of children 1–59 months old were reported. The rate of diarrhea-associated deaths decreased by 41%, from 2.36/100,00 in 2005–2006 to 1.38/100,000 in 2022–2024. Mortality rates were higher among infants 1–3 months old, males, Black children and non-Hispanic children. Differences in mortality rates across demographic groups decreased over time. Overall, 94% of diarrhea-associated deaths were of unspecified etiology. Before vaccine introduction, diarrhea-associated death rates were higher during the rotavirus season (January to June) within the 4–11 and 12–23 months age groups; however, no distinct seasonality was observed after vaccine introduction (2008–2024). Conclusions: Diarrhea-associated mortality has declined in the United States. The diminished seasonality of deaths during the rotavirus season in the age groups most susceptible to rotavirus suggests that vaccines likely contributed, among other factors, to declines in US diarrhea-associated mortality over the past 2 decades. However, the lack of specified etiology for most diarrhea-associated deaths precludes definitive attribution.

  • Evaluation of Rotavirus Vaccine Effectiveness by Severity of Rotavirus Disease: Findings From the MNSSTER-V Project

    by Mary C. Moran, Jordan Cates, Neha Balachandran, Jazmina Umana, Helah Safi, Hammarskjold Makhuza, Volga Iniguez, Nguyen Van Trang, Isidore Bonkoungou, Cissy Nalunkuma, et al.

    Background: Since the introduction of rotavirus vaccines, acute gastroenteritis (AGE) hospitalizations due to rotavirus have decreased globally; however, vaccine effectiveness (VE) differs by country, age and disease severity. We evaluated rotavirus VE by disease severity in different age groups and under-5 childhood mortality (U5M) strata. Methods: The Vesikari score is a common measure of AGE disease severity. A modified Vesikari Score (mVS) was calculated for 18,426 children with medically attended AGE across 16 countries from the Multi-National Subpopulations Study To Evaluate Rotavirus Vaccines dataset. Using a test-negative case–control design (cases had rotavirus-positive AGE and controls had rotavirus-negative AGE), we calculated complete rotavirus series VE against different severity categories among children 6–59 months old, stratified by age and country U5M level, respectively. Results: VE increased with increasing disease severity: 38% (95% confidence interval [CI]:17–53) for mild/moderate disease versus 58% (95% CI: 50–64) for severe/very severe disease, and this pattern persisted with stratification by age and U5M. Among children with severe/very severe disease, VE was higher in infants 6–11 months (62%, 95% CI: 51–70) compared with children 24–59 months old (11%, 95% CI: −78 to 56), and lower among children in the highest U5M strata (44%, 95% CI: 26–58) compared to children in the high U5M strata (60%, 95% CI: 47–69). Conclusions: Rotavirus vaccines provide the greatest protection against very severe rotavirus disease. VE remains lower in countries with higher U5M levels, even among children with very severe rotavirus disease, highlighting the need for improved vaccine performance in countries with high disease burden.


  • CLDN1 knock out keratinocytes as a model to investigate multiple skin disorders

    by Kimberly A. Arnold, Mary C. Moran, Huishan Shi, Ivonne M. J. J. van Vlijmen‐Willems, Diana Rodijk‐Olthuis, Jos P. H. Smits, Matthew G. Brewer

    The transmembrane protein claudin‐1 is critical for formation of the epidermal barrier structure called tight junctions (TJ) and has been shown to be important in multiple disease states. These include neonatal ichthyosis and sclerosing cholangitis syndrome, atopic dermatitis and various viral infections. To develop a model to investigate the role of claudin‐1 in different disease settings, we used CRISPR/Cas9 to generate human immortalized keratinocyte (KC) lines lacking claudin‐1 (CLDN1 KO). We then determined whether loss of claudin‐1 expression affects epidermal barrier formation/function and KC differentiation/stratification. The absence of claudin‐1 resulted in significantly reduced barrier function in both monolayer and organotypic cultures. CLDN1 KO cells demonstrated decreases in gene transcripts encoding the barrier protein filaggrin and the differentiation marker cytokeratin‐10. Marked morphological differences were also observed in CLDN1 KO organotypic cultures including diminished stratification and reduced formation of the stratum granulosum. We also detected increased proliferative KC in the basale layer of CLDN1 KO organotypic cultures. These results further support the role of claudin‐1 in epidermal barrier and suggest an additional role of this protein in appropriate stratification of the epidermis.


  • Open Access

    S. aureus virulence factors decrease epithelial barrier function and increase susceptibility to viral infection

    by Mary C. Moran, Matthew G. Brewer, Patrick M. Schlievert, Lisa A. Beck

    Individuals with atopic dermatitis (AD) are highly colonized by Staphylococcus aureus and are more susceptible to severe viral complications. We hypothesized that S. aureus secreted virulence factors may alter keratinocyte biology to enhance viral susceptibility through disruption of the skin barrier, impaired keratinocyte differentiation, and/or inflammation. To address this hypothesis, human keratinocytes were exposed to conditioned media from multiple S. aureus strains that vary in virulence factor production (USA300, HG003, and RN4220) or select purified virulence factors. We have identified the S. aureus enterotoxin- like superantigen SE l Q, as a virulence factor of interest, since it is highly produced by USA300 and was detected on the skin of 53% of AD subjects ( n = 72) in a study conducted by our group. Treatment with USA300 conditioned media or purified SE l Q resulted in a significant increase in keratinocyte susceptibility to infection with vaccinia virus, and also significantly decreased barrier function. Importantly, we have previously demonstrated that keratinocyte differentiation influences susceptibility to viral infection, and our qPCR observations indicated that USA300 S. aureus and SE l Q alter differentiation in keratinocytes. CRISPR/Cas9 was used to knock out CD40, a potential enterotoxin receptor on epithelial cells. We found that CD40 expression on keratinocytes was not completely necessary for SE l Q-mediated responses, as measured by proinflammatory cytokine expression and barrier function. Together, these findings support that select S. aureus virulence factors, particularly SE l Q, enhance the susceptibility of epidermal cells to viral infection, which may contribute to the increased cutaneous infections observed in individuals with AD. Importance: Staphylococcus aureus skin colonization and infection are frequently observed in individuals with atopic dermatitis. Many S. aureus strains belong to the clonal group USA300, and these strains produce superantigens including the staphylococcal enterotoxin- like Q (SE l Q). Our studies highlight that SE l Q may play a key role by altering keratinocyte differentiation and reducing barrier function; collectively, this may explain the AD-specific enhanced infection risk to cutaneous viruses. It is unclear what receptor mediates SE l Q’s effects on keratinocytes. We have shown that one putative surface receptor, CD40, was not critical for its effects on proinflammatory cytokine production or barrier function.


  • Open Access

    History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis

    by Mary C. Moran, Alanna Klose, Takeshi Yoshida, Anna De Benedetto, Lynda C. Schneider, Peck Y. Ong, Eric L. Simpson, Donald Y. M. Leung, Benjamin L. Miller, Christopher L. Seplaki, et al.

    Introduction Patients with atopic dermatitis (AD) are uniquely susceptible to a number of serious viral skin complications, including eczema herpeticum (EH), caused by herpes simplex virus. This study explored the associations between biomarkers of epithelial barrier dysfunction, type 2 immunity, Staphylococcus aureus infection, and S. aureus-specific immunoglobulin responses in a cohort of AD subjects with and without a history of EH (EH+ and EH−, respectively). Methods A total of 112 subjects with AD (56 EH+, 56 EH−), matched by age and AD severity, were selected from a registry of over 3000 AD subjects. Logistic regression was used to test the association between history of S. aureus skin infection and history of EH, while controlling for a number of confounders. Results Compared to those without a history of S. aureus skin infection, subjects with a history of S. aureus skin infection were found to have more than sixfold increased odds of having a history of EH (6.60, 95% confidence interval [CI]: 2.00–21.83), after adjusting for history of other viral skin infections (molluscum contagiosum virus, human papillomavirus), serum total IgE, and IgG against the S. aureus virulence factor SElX. Conclusions These findings indicate an important relationship between S. aureus skin infections and EH.


  • Stage of Keratinocyte Differentiation Is a Key Determinant of Viral Susceptibility in Human Skin

    by Mary C. Moran, Ellen Chinchilli, H. Mark Kenney, Eleanor M. Pope, Glynis Scott, Matthew G. Brewer, Lisa A. Beck


  • Open Access

    Supply Chain Disruptions during COVID-19 Pandemic Uncover Differences in Keratinocyte Culture Media

    by Mary C. Moran, Eleanor M. Pope, Matthew G. Brewer, Lisa A. Beck


  • Open Access

    Conditions That Simulate the Environment of Atopic Dermatitis Enhance Susceptibility of Human Keratinocytes to Vaccinia Virus

    by Matthew G. Brewer, Stephanie R. Monticelli, Mary C. Moran, Benjamin L. Miller, Lisa A. Beck, Brian M. Ward

    Individuals with underlying chronic skin conditions, notably atopic dermatitis (AD), are disproportionately affected by infections from members of the herpesviridae, papovaviridae, and poxviridae families. Many patients with AD experience recurrent, widespread cutaneous viral infections that can lead to viremia, serious organ complications, and even death. Little is known about how the type 2 inflammatory environment observed in the skin of AD patients impacts the susceptibility of epidermal cells (keratinocytes) to viral pathogens. Herein, we studied the susceptibility of keratinocytes to the prototypical poxvirus, vaccinia virus (VV)—the causative agent of eczema vaccinatum—under conditions that simulate the epidermal environment observed in AD. Treatment of keratinocytes with type 2 cytokines (IL-4 and -13) to simulate the inflammatory environment or a tight junction disrupting peptide to mirror the barrier disruption observed in AD patients, resulted in a differentiation-dependent increase in susceptibility to VV. Furthermore, pan JAK inhibition was able to diminish the VV susceptibility occurring in keratinocytes exposed to type 2 cytokines. We propose that in AD, the increased viral susceptibility of keratinocytes leads to enhanced virus production in the skin, which contributes to the rampant dissemination and pathology seen within patients.


  • Open Access

    Period Poverty: A Risk Factor for People Who Menstruate in STEM

    by Katherine Andersh, Zanah Francis, Mary Moran, Emily Quarato

    In the United States, lack of access to menstrual hygiene products (MHPs) is contributing to a serious problem, period poverty. Period poverty has negative impacts on physical and mental health, as well as long term decreased productivity in educational and professional outcomes. Therefore, it is critical that action be taken to reduce period poverty and improve menstrual equity particularly for young menstruators, as inaction can result in lasting negative effects on both health and prosperity. The inability to afford and access MHPs results in recurring absences from school, which is a critical time for nurturing interest in science, technology, engineering, and mathematics (STEM). To ensure the development of a diverse STEM workforce, significant action needs to be taken to reduce period poverty and improve menstrual equity. We recommend instituting a requirement that all public K-12 schools provide free MHPs to students, an expansion of Section 2 of the Menstrual Equity for All Act of 2019 (ME4ALL Act, H.R. 1882).


  • Open Access

    Characterization of Human Keratinocyte Cell Lines for Barrier Studies

    by Mary C. Moran, Radha P. Pandya, Kimberly A. Leffler, Takeshi Yoshida, Lisa A. Beck, Matthew G. Brewer